WEDNESDAY, Oct. 6 (HealthDay News) -- A new experimental drug
for treating patients who have acute heart failure plus kidney
failure did not show any overall benefit, indicating that the
future of this particular drug, called rolofylline, is over.
"I think this is the end of the story for this drug," said Dr. Barry Massie, lead author of a study appearing in the Oct. 7 issue of the New England Journal of Medicine. "There was a very promising pilot trial but these results . . . were neutral. I am disappointed," he said.
The results were presented last year at the European Society of
Cardiology meeting. Shortly before that, drug company Merck, which
has been developing the medicine and which funded this study,
announced that it would not be filing for U.S. Food and Drug
Administration approval for rolofylline.
Rolofylline is known as an A1-receptor antagonist and is
intended to make diuretics work more effectively.
Other drugs in the same class of medications that were developed
by other companies have met with similarly disappointing results
after promising early results, said Massie, who is chief of the
cardiology division at the San Francisco VA Medical Center and
professor of medicine at the University of California, San
He explained that kidney problems are a major complication of
heart failure and "those patients who develop renal [kidney]
failure in the course of treatment have a much higher hospital
admission and death rate."
This may be at least partly because patients are taken off of
certain cardiac medications in order to improve kidney
"This is sort of a perfect storm," Massie said.
For this study, just over 2,000 patients who had been
hospitalized for acute heart failure and kidney problems were
randomly assigned to receive a placebo or 30 milligrams of
rolofylline daily intravenously. Treatment lasted for up to three
Rolofylline did not prolong survival or improve heart failure or
kidney function when compared with the placebo.
And in contrast to the placebo group, some patients taking
rolofylline had seizures, indicating that the drug was able to
cross the blood-brain barrier. Seizures are a potential side effect
for this class of drugs.
"[We] had hoped that the drug didn't cross the blood-brain barrier," Massie said.
One expert was similarly disappointed with the study
"Rolofylline certainly does not seem to have benefit in terms of risk of mortality (or death) and hospital readmission," noted Dr. Tara Narula, a cardiologist with Lenox Hill Hospital in New York City. "At this point, unfortunately, we're left with what we have in our arsenal, which we've [already] had for many years."
That includes IV loop diuretics, ACE inhibitors and beta
blockers, she said.
There's more on heart failure at the
American Heart Association.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.